Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
10.3233/JPD-191900 29 ChuangY
The bill would require MassHealth to cover FDA-approved anti-obesity medications (including Wegovy, Saxenda, and Zepbound) for any enrollee with: BMI 30, or BMI 27 with at least one weight-related comorbidity The bill includes a fiscal note estimating first-year cost of $680 million, assuming 6% uptake among eligible enrollees
The placebo group received volume-matched saline injections on the same schedule
Legal and Regulatory Considerations The FDA has issued multiple warnings about compounded semaglutide products, clarifying that pharmacies may not legally compound medications that are essentially copies of commercially available, FDA-approved drugs unless a specific ingredient shortage exists
